Investigation of the relationship between regression of hypertensive cardiac hypertrophy and improvement of cardiac sympathetic nervous dysfunction using iodine-123 metaiodobenzylguanidine myocardial imaging

European Journal of Nuclear Medicine

Volumn 23, Issue 7, 1996, Pages 756-761

  Morimoto, Satoshi ^a,b   Terada, Koji ^a   Keira, Natsuya ^a   Satoda, Masahiko ^a   Inoue, Keiji ^a   Tatsukawa, Hirotaka ^a   Katoh, Shuji ^a   Ida, Kazunori ^a   Sugihara, Hiroki ^b   Takeda, Kazuo ^b   Nakagawa, Masao ^b  

^a ASAHI UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Antihypertensive therapy; Cardiac sympathetic nervous dysfunction; Hypertensive cardiac hypertrophy; Iodine 123 metaiodobenzylguanidine; Regression

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; IODINE 123;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HUMAN; MALE; NERVE FUNCTION; SYMPATHETIC NERVE;

3-IODOBENZYLGUANIDINE; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; CONTRAST MEDIA; ECHOCARDIOGRAPHY; FEMALE; HEART; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IODINE RADIOISOTOPES; IODOBENZENES; MALE; MIDDLE AGED; SYMPATHETIC NERVOUS SYSTEM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 8944239409     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00843703     Document Type: Article

References (27)

1. Sasayama S, Ross J Jr, Franklin D, Bloor CM, Bishop S, Dilley RB. Adaptations of the left ventricle to chronic pressure overload. Circ Res 1976; 38: 172-178.
2. Levy D, Garrison RJ. Savage DD. Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566
3. Dahloef B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
4. Sisson JC, Wieland DM, Sherman P, Mangner TJ, Tobes MC, Jacques S Jr. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 1987; 28: 1620-1624.
5. Jaques S Jr, Tobes MC, Sisson JC, Baker JA, Wieland DM. Comparison of the sodium dependency of uptake of metaiodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol 1984; 26: 539-546
6. 123I] and [131] metaiodobenzyl-guanidine: concise communication. J Nucl Med 1981; 22: 358-364.
7. Gasnier B, Roisin MP, Scherman D, Coornaert S. Desplanches G, Henry JP. Uptake of meta-iodobenzylguanidine by bovine chromaffin granule membranes. Mol Pharmacol 1986; 29: 275-280.
8. Jaques S Jr, Tobes MC. Comparison of the secretary mechanisms of metaiodobenzylguanidine (MIBG) and norepinephrine (NE) from cultured bovine adrenomedullary cells. J Nucl Med 1985; 26: 17.
9. Kline RC, Swanson DP, Wieland DM. Myocardial imaging in man with 1-123 meta-iodobenzylguanidine. J Nucl Med 1981; 22: 129-132.
10. Henderson EB, Kahn JK, Corbett JR, Jansen DE, Pippin JJ, Kulkarni P, Ugolini V, Akers MS, Hansen C, Buja LM, Parkey RW, Willerson JT. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988; 78: 1192-1199.
11. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man; anatomic validation of the method. Circulation 1977; 55: 613-618.
12. Merlet P, Valette H, Dubous-Rande JL, Moyse D, Duboc D, Dove P, Bourguignon MH, Benvenuti C, Duval AM, Agostini D, Loisance D, Castaigne A, Syrota A. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33: 471-477.
13. Dunn FG, Chandraratna P, deCarvalho JGR, Basta LL. Frohlich ED. Pathophysiologic assessment of hypertensive heart disease with echocardiography. Am J Cardiol 1977; 39: 789-795.
14. Dunn FG, Oigman W, Ventura HO, Messerli FH, Kobrin I, Frohlich ED. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 1984; 53: 105-108.
15. Tan LB, Brilla C, Weber KT. Prevention of structural changes in the heart in hypertension by angiotensin converting enzyme inhibition. J Hypertens 1992; 10:531-534
16. Arita M, Fujiwara S, Ueno Y, Shiotani M, Nakamuru Y. Nakatsu C, Nishio I, Masuyama Y. Regression of left ventricular hypertrophy in hypertensive patients: responses to exercise by antihypertensive treatment. Jpn Circ J 1990; 54: 575-580.
17. Corea L, Bentivoglio M, Verdecchia P. Reversal of left ventricular hypertrophy in essential hypertension by early and long-term treatment with methyldopa. Clin Trial J 1981; 18: 380-394.
18. Corea L, Bentivoglio M, Verdecchia P, Motolese M. Plasma norepinephrine and left ventricular hypertrophy in systemic hypertension. Am J Cardiol 1984; 53: 1299-1303.
19. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha I adrenergic response. J Clin Invest 1985; 74: 732-738.
20. Strauer BE, Mahmoud MA, Bayer F, Bohn I, Motz U. Reversal of left ventricular hypertrophy and improvement of cardiac function in man by nifedipine. Eur Heart J 1984; 5: 53-60.
21. Tsuchimochi S, Tamaka N, Tadamura E, Kawamoto M, Fujita T, Yonekura Y, Konishi J. Age and gender differences in normal myocardial adrenergic neuronal function evaluated by iodine-123-MIBG imaging. J Nucl Med 1995; 36: 969-974.
22. Schofer J, Spilmann R, Schucert A, Weber K, Schluter M. Iodine-123 metaiodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988; 119: 1252-1258.
23. 123I-metaiodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J 1990; 119: 1329-1337.
24. Gill JS, Hunter GJ, Gane G, Camm AJ. Heterogeneity of the human myocardial sympathetic innervation: in vivo demonstration by iodine 123-labeled metaiodobenzylguanidine scintigraphy. Am Heart J 1993; 126: 390-398.
25. Thames MD, Klopfenstein HS, Abboud FM, Mark AL, Walker JL. Preferential distribution of inhibitory cardiac receptors with vagal afferents to the inferoposterior wall of the left ventricle activated coronary occlusion in the dog. Cric Res 1978; 43: 512-519.
26. Khafagi FA, Shapiro B, Fig LM, Mallette S, Sisson JC. Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 1989; 30: 481-489.
27. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzyl-guanidine (MIBG). Nucl Med Commun 1992; 13: 513-521.